Discover concise prescribing info for Serc topical on MIMS including its uses, special precautions, interactions, dosages etc.

Adult: For the treatment of vertigo, tinnitus, hearing loss, and nausea associated with Meniere's disease: As betahistine dihydrochloride: Initially, 8-16 mg tid. Maintenance: 24-48 mg daily in divided doses. As betahistine mesilate: 6-12 mg tid. Adjust doses according to patient needs. May be taken with or without food.

Find comprehensive medication information and prescription drugs in our trusted drug directory. Stay informed with the latest medical insights on our drug website. Visit us today for more details.

Indications, side effects, contraindications and other prescribing information for Serc on MIMS

2021年6月24日 · Betahistine is a histamine blocker that treats symptoms of vertigo. What is Serc used for? It treats Ménière’s syndrome, a condition caused by the pressure of excess fluid in the inner ear. How should I take Serc? The tablets should be swallowed whole with a sufficient quantity of liquid (e.g. one glass of water). Take it with or without food.

Serc tablets contain the active ingredient betahistine dihydrochloride. Serc works by improving the blood flow of the inner ear and restoring it to normal. It also acts on the nerve endings in the inner ear to normalise the way in which the nerves respond to outside influences.

SERC contains the active ingredient betahistine dihydrochloride. SERC is used to treat a disorder of your inner ear. This disorder may include one or more of the following symptoms, in one or both ears: ringing in the ears (tinnitus), loss of clear hearing and problems with balance (vertigo).

Indications, side effects, contraindications and other prescribing information for Nausea, vomiting drugs on MIMS

Buy SERC Betahistine Hydrochloride 16mg Tablet 1's from ₱0.00 2 hours delivery Book at MedsGo Pharmacy

Serc® (Betaserc®, Vasomotal®, betahistine dihydrochloride) of Solvay Pharmaceuticals is the world market leader in the treatment of Ménière’s disease and vestibular vertigo. Serc® was first registered in Europe in 1970 for the treatment of Ménière’s disease.